all report title image
  • Published On : May 2023
  • Code : CMI5719
  • Industry : Pharmaceutical
  • Pages : 150
  • Formats :

The Insulin Lispro market has been significant due to the increasing prevalence of diabetes globally. The global Insulin Lispro market size was valued at US$ 3.92 billion in 2022, and is projected to reach US$ 5.54 billion by 2030 at a CAGR of 4.4% from 2023 to 2030.

Factors contributing to the growth of the Insulin Lispro market include the rising incidence of diabetes, increasing awareness and diagnosis of the disease, and advancements in insulin delivery devices. Additionally, the development of biosimilar versions of Insulin Lispro may also contribute to market expansion.

Insulin Lispro Market Regional Insights

  1. North America: North America has been a prominent market for insulin, driven by a high prevalence of diabetes and a well-established healthcare system. The United States, in particular, has a large market for insulin products, including Insulin Lispro.
  2. Europe: Europe also has a significant market for insulin, with countries such as Germany, France, and the United Kingdom being major contributors. The region has a well-developed healthcare infrastructure and a high prevalence of diabetes.
  3. Asia Pacific: The Asia Pacific region has witnessed rapid growth in the insulin market due to the increasing prevalence of diabetes, a growing aging population, and changing lifestyles. Countries like China and India have a substantial market for insulin products.

Insulin Lispro Market Drivers:

  1. Increasing Prevalence of Diabetes: The rising prevalence of diabetes worldwide is a significant driver for the Insulin Lispro market. As the number of individuals diagnosed with diabetes continues to increase, there is a growing demand for insulin products like Insulin Lispro to manage blood sugar levels effectively.
  2. Advancements in Insulin Delivery Devices: Continuous advancements in insulin delivery devices, such as insulin pens and pumps, have improved the convenience and ease of insulin administration. These advancements have increased patient compliance and the adoption of insulin therapies, thereby driving the demand for Insulin Lispro.
  3. Technological Innovations and Product Development: Ongoing research and development efforts have led to the development of newer and more advanced insulin analogs like Insulin Lispro. These analogs offer improved pharmacokinetics, faster onset of action, and better glycemic control, leading to increased demand in the market.
  4. Aging Population and Lifestyle Changes: The aging population and lifestyle changes, including sedentary lifestyles, unhealthy diets, and obesity, contribute to the increasing incidence of diabetes. As these factors continue to rise, there is a higher demand for insulin products like Insulin Lispro to manage diabetes effectively.

Insulin Lispro Market Opportunities:

  1. Development of Biosimilar Insulin Lispro: The development and introduction of biosimilar versions of Insulin Lispro provide opportunities for cost-effective alternatives to the branded product. Biosimilars can increase access to insulin therapy, especially in regions with limited affordability, thereby expanding the market.
  2. Personalized Medicine and Precision Insulin Therapy: The concept of personalized medicine, including precision insulin therapy, is gaining traction. Advancements in technology and genetic profiling allow for customized insulin treatment plans based on an individual's unique needs. Insulin Lispro can be a key component of precision medicine approaches, presenting opportunities for targeted therapies.
  3. Increasing Adoption of Insulin Pump Therapy: Insulin pump therapy offers improved glycemic control and flexibility in insulin administration. The increasing adoption of insulin pump therapy presents opportunities for Insulin Lispro, which is compatible with various insulin pump devices. The convenience and precision of insulin pump therapy can drive the demand for Insulin Lispro.
  4. Technological Advancements in Insulin Delivery Devices: Ongoing advancements in insulin delivery devices, such as smart insulin pens and connected devices, create opportunities for Insulin Lispro. These technologies enhance insulin administration, dose tracking, and data management, improving patient adherence and outcomes.

Insulin Lispro Market Trends:

  1. Increasing Adoption of Continuous Glucose Monitoring (CGM): Continuous Glucose Monitoring devices are becoming more widely used for diabetes management. CGM systems provide real-time glucose readings, helping individuals make informed decisions about insulin dosing. The integration of CGM with insulin pumps and smart devices creates a trend towards personalized insulin therapy and improved glycemic control.
  2. Shift Towards Ultra-rapid Acting Insulins: Ultra-rapid acting insulins, including Insulin Lispro, are gaining popularity in the market. These insulins have a faster onset of action, mimicking the body's natural insulin response more closely. They allow for more flexible dosing and can be beneficial in managing postprandial blood sugar spikes.
  3. Growing Interest in Closed-loop Systems (Artificial Pancreas): Closed-loop systems, also known as artificial pancreas systems, combine CGM with insulin pump therapy to automate insulin delivery based on glucose levels. This trend is driven by advancements in algorithm technology and offers improved glucose control, reducing the burden of diabetes management for individuals.
  4. Focus on Patient-Centric Insulin Delivery: There is an increasing emphasis on patient-centric insulin delivery solutions, aiming to simplify insulin administration and improve patient experience. This includes the development of user-friendly insulin pens, smart insulin devices, and connected health solutions that facilitate insulin management, dosing accuracy, and adherence.
CMI table icon

Insulin Lispro Market Report Coverage

Report Coverage Details
Base Year: 2022 Market Size in 2022: US$ 3.92 Bn
Historical Data for: 2017 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 4.4% 2030 Value Projection: US$ 5.54 Bn
Geographies covered:
  • North America: U.S. and Canada
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Middle East and Africa: GCC Countries, Israel, Rest of Middle East, South Africa, North Africa, and Central Africa
Segments covered:
  • By Type of Insulin Lispro: Rapid-acting Insulin Lispro, Long-acting Insulin Lispro
  • By Delivery Method: Insulin Pens, Insulin Syringes, Insulin Pumps
  • By Indication: Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes, Others
  • By Age Group: Pediatric Patients, Adult Patients, Geriatric Patients
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
  • By Brand: Humalog (Eli Lilly and Company), Admelog (Sanofi), Other Brands
Companies covered:

Eli Lilly and Company, Sanofi, Novo Nordisk A/S, Merck & Co., Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca PLC, Johnson & Johnson Services, Inc., Biocon Limited, Mylan N.V., Boehringer Ingelheim International GmbH, Wockhardt Ltd., Lupin Pharmaceuticals, Inc., Bioton S.A., Ypsomed AG

Growth Drivers:
  • Increasing Prevalence of Diabetes
  • Advancements in Insulin Delivery Devices
  • Technological Innovations and Product Development
  • Aging Population and Lifestyle Changes
Restraints & Challenges:
  • Cost and Affordability
  • Limited Healthcare Infrastructure
  • Potential Side Effects and Safety Concerns

Insulin Lispro Market Restraints:

  1. Cost and Affordability: Insulin therapy can be expensive, particularly for individuals without adequate insurance coverage or in regions with limited healthcare resources. The cost of Insulin Lispro and other insulin products may pose a barrier to access and affordability, limiting market growth.
  2. Limited Healthcare Infrastructure: In some regions, especially low- and middle-income countries, the healthcare infrastructure may be insufficient to support effective diabetes management. Limited access to healthcare facilities, diagnostics, and trained healthcare professionals can hinder the widespread adoption of Insulin Lispro.
  3. Potential Side Effects and Safety Concerns: Although insulin therapy is generally safe and well-tolerated, there can be side effects and safety concerns associated with its use. Hypoglycemia, weight gain, injection site reactions, and the risk of allergic reactions are potential factors that may affect patient acceptance and usage of Insulin Lispro.

Insulin Lispro Market New product launches including year

  1. Admelog (Insulin Lispro Injection) - Admelog, a biosimilar version of Insulin Lispro, was launched in the United States in 2018 by Sanofi. It is indicated for the treatment of both type 1 and type 2 diabetes.
  2. Insulin Lispro Sanofi (Insulin Lispro) - In 2019, Sanofi launched its own branded version of Insulin Lispro, known as Insulin Lispro Sanofi, in certain European countries. It was introduced as a fast-acting insulin to help manage blood sugar levels in people with diabetes.
  3. Insulin Lispro Injection (Authorized Generic) - Eli Lilly and Company introduced an authorized generic version of Humalog (Insulin Lispro) in 2019 in the United States. An authorized generic is essentially the same medication as the branded product but is marketed under a different name.

Acquisition and partnerships in Insulin Lispro Market

  1. Sanofi and Zealand Pharma: In 2018, Sanofi and Zealand Pharma entered into a global licensing and collaboration agreement for the development and commercialization of multiple peptide-based therapies, including glucose-dependent insulinotropic polypeptide (GIP) receptor agonists. The partnership aimed to develop innovative treatments for diabetes, potentially complementing the use of Insulin Lispro.
  2. Novo Nordisk and Glooko: In 2018, Novo Nordisk and Glooko announced a partnership to develop digital health solutions for diabetes management. The collaboration aimed to integrate Novo Nordisk's insulin delivery systems with Glooko's digital platform, enabling better tracking and management of insulin therapy, including Insulin Lispro.
  3. Eli Lilly and Company (Lilly) and Ypsomed: In 2020, Lilly and Ypsomed entered into a non-exclusive, global partnership to create and commercialize automated insulin delivery systems. The collaboration aimed to integrate Lilly's insulin products, including Insulin Lispro, with Ypsomed's insulin pump technologies to improve insulin therapy options for people with diabetes.

Top companies in Insulin Lispro Market

  1. Eli Lilly and Company
  2. Sanofi
  3. Novo Nordisk A/S
  4. Merck & Co., Inc.
  5. Pfizer Inc.
  6. F. Hoffmann-La Roche Ltd.
  7. AstraZeneca PLC
  8. Johnson & Johnson Services, Inc.
  9. Biocon Limited
  10. Mylan N.V.
  11. Boehringer Ingelheim International GmbH
  12. Wockhardt Ltd.
  13. Lupin Pharmaceuticals, Inc.
  14. Bioton S.A.
  15. Ypsomed AG

Insulin lispro is used to treat type 1 diabetes (condition in which the body does not produce insulin and cannot control the amount of sugar in the blood) in people who need insulin therapy. It is always used with another type of insulin, unless it is being used in an external insulin pump. Insulin lispro injection products are also used to improve glycemic control in adults with type 2 diabetes who do not respond well to oral medications alone. Insulin lispro is an analog insulin that differs from human insulin with a change in the sequence of two amino acids, proline at B-28 and lysine at B-29. This change prevents insulin from forming dimers and hexamers, which have lower activity than monomeric insulin. Insulin lispro is rapidly absorbed following subcutaneous administration, reaching peak levels within 2-4 hours and remains effective for 18-30 hours.

Market Dynamics:

The global insulin market has grown significantly in recent years, primarily due to an increase in the number of people living with diabetes and technological advancements in the field of insulin delivery devices. This growth is further expected to be supported by factors such as increasing government initiatives to improve healthcare and rising patient demand for insulin, as well as favorable medical reimbursement policies in developed countries.

Changing lifestyles, such as an increased adoption of sedentary habits and unhealthy diets, have resulted in an increased number of people developing diabetes globally. According to the International Diabetes Federation, there are approximately 382 million people who have diabetes worldwide, and this number is expected to rise to 592 million by 2035. This is likely to fuel the demand for insulin, thereby driving market growth.

However, the market was negatively impacted due to lower diagnosis rate during Covid-19 pandemic.

Key features of the study:

  • This report provides in-depth analysis of the global insulin lispro market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global insulin lispro market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Eli Lilly and Company, Sanofi, Novo Nordisk A/S, Merck & Co., Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca PLC, Johnson & Johnson Services, Inc., Biocon Limited, Mylan N.V., Boehringer Ingelheim, International GmbH, Wockhardt Ltd., Lupin Pharmaceuticals, Inc., Bioton S.A., and Ypsomed AG          
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global insulin lispro market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global insulin lispro market

Detailed Segmentation:

  • Global Insulin Lispro Market, By Type of Insulin Lispro
    • Rapid-acting Insulin Lispro
    • Long-acting Insulin Lispro
  • Global Insulin Lispro Market, By Delivery Method
    • Insulin Pens
    • Insulin Syringes
    • Insulin Pumps
  • Global Insulin Lispro Market, By Indication
    • Type 1 Diabetes
    • Type 2 Diabetes
    • Gestational Diabetes
    • Others
  • Global Insulin Lispro Market, By Age Group
    • Pediatric Patients
    • Adult Patients
    • Geriatric Patients
  • Global Insulin Lispro Market, By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Insulin Lispro Market, By Brand
    • Humalog (Eli Lilly and Company)
    • Admelog (Sanofi)
    • Other Brands
  • Global Insulin Lispro Market, By Geography
    • North America
    • Europe
    • Asia Pacific
    • South America
    • Middle East & Africa
  • Company Profiles
    • Eli Lilly and Company
    • Sanofi
    • Novo Nordisk A/S
    • Merck & Co., Inc.
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd.
    • AstraZeneca PLC
    • Johnson & Johnson Services, Inc.
    • Biocon Limited
    • Mylan N.V.
    • Boehringer Ingelheim International GmbH
    • Wockhardt Ltd.
    • Lupin Pharmaceuticals, Inc.
    • Bioton S.A.
    • Ypsomed AG

Frequently Asked Questions

The  global insulin lispro market size was valued at US$ 3.92 Bn in 2022 and is expected to reach US$ 5.54 Bn by 2030.
The drivers include the increasing prevalence of diabetes, advancements in insulin delivery devices, technological innovations in the market.
The market is segmented based on the type of Insulin Lispro, delivery method, indication, age group, distribution channel, region, and brand.
The market growing at a CAGR of 4.4% during the forecast period.
Eli Lilly and Company, Sanofi, Novo Nordisk A/S, Merck & Co., Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca PLC, Johnson & Johnson Services, Inc., Biocon Limited, Mylan N.V., Boehringer Ingelheim International GmbH, Wockhardt Ltd., Lupin Pharmaceuticals, Inc., Bioton S.A., Ypsomed AG

Related Reports


Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo